Articles
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer
(KEYNOTE-010): a randomised controlled trial
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis,
Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro Jr, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im,
Marisa Dolled-Filhart, Edward B Garon
Summary
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need Published Online
for eff ective treatments for progressive disease. We assessed the effi cacy of pembrolizumab for patients with December 19, 2015
previously treated, PD-L1-positive, advanced non-small-cell lung cancer. http://dx.doi.org/10.1016/
S0140-6736(15)01281-7
See Online/Comment
Methods We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients
http://dx.doi.org/10.1016/
with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly S0140-6736(15)01308-2
assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab Yale School of Medicine, Yale
2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m² every 3 weeks. The primary endpoints were overall survival Cancer Center, and Smilow
and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of Cancer Hospital, New Haven,
CT, USA (Prof R S Herbst MD);
tumour cells. We used a threshold for signifi cance of p<0·00825 (one-sided) for the analysis of overall survival and a
The Netherlands Cancer
threshold of p<0·001 for progression-free survival. This trial is registered at ClinicalTrials.gov, number NCT01905657. Institute and The Academic
Medical Hospital Amsterdam,
Findings Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, Amsterdam, Netherlands
(Prof P Baas MD); Seoul National
346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel. By Sept 30, 2015, 521 patients had died. In
University Hospital, Seoul,
the total population, median overall survival was 10·4 months with pembrolizumab 2 mg/kg, 12·7 months with South Korea (D-W Kim MD); Vall
pembrolizumab 10 mg/kg, and 8·5 months with docetaxel. Overall survival was signifi cantly longer for pembrolizumab D’Hebron University Hospital
2 mg/kg versus docetaxel (hazard ratio [HR] 0·71, 95% CI 0·58–0·88; p=0·0008) and for pembrolizumab 10 mg/kg and Vall d’Hebron Institute of
Oncology, Barcelona, Spain
versus docetaxel (0·61, 0·49–0·75; p<0·0001). Median progression-free survival was 3·9 months with pembrolizumab
(E Felip MD); Clinica Universidad
2 mg/kg, 4·0 months with pembrolizumab 10 mg/kg, and 4·0 months with docetaxel, with no signifi cant diff erence de Navarra, Pamplona, Spain
for pembrolizumab 2 mg/kg versus docetaxel (0·88, 0·74–1·05; p=0·07) or for pembrolizumab 10 mg/kg versus (J L Pérez-Gracia MD); National
docetaxel (HR 0·79, 95% CI 0·66–0·94; p=0·004). Among patients with at least 50% of tumour cells expressing Cancer Center, Goyang, South
Korea (Prof J-Y Han MD); Mayo
PD-L1, overall survival was signifi cantly longer with pembrolizumab 2 mg/kg than with docetaxel (median
Clinic, Rochester, MN, USA
14·9 months vs 8·2 months; HR 0·54, 95% CI 0·38–0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with (J Molina MD); CHA Bundang
docetaxel (17·3 months vs 8·2 months; 0·50, 0·36–0·70; p<0·0001). Likewise, for this patient population, progression- Medical Center, CHA University,
free survival was signifi cantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 months vs
Gyeonggi-do, South Korea
(Prof J-H Kim MD); Centre
4·1 months; HR 0·59, 95% CI 0·44–0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with docetaxel
François Baclesse, Caen, France
(5·2 months vs 4·1 months; 0·59, 0·45–0·78; p<0·0001). Grade 3–5 treatment-related adverse events were less (C Dubos Arvis MD); Samsung
common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given Medical Center Sungkyunkwan
University School of Medicine,
10 mg/kg, and 109 [35%] of 309 given docetaxel).
Seoul, South Korea
(Prof M-J Ahn MD); Hospital de
Interpretation Pembrolizumab prolongs overall survival and has a favourable benefi t-to-risk profi le in patients with la Santa Creu i Sant Pau,
previously treated, PD-L1-positive, advanced non-small-cell lung cancer. These data establish pembrolizumab as a Barcelona, Spain
(M Majem MD); Rush University
new treatment option for this population and validate the use of PD-L1 selection.
Medical Center, Chicago, IL,
USA (M J Fidler MD); Instituto
Funding Merck & Co. do Câncer do Estado de São
Paulo, São Paulo, Brazil
Introduction expressed on activated B and T cells that normally down- (G de Castro MD); Pontificia
Universidad Católica de Chile,
Although treatment for non-small-cell lung cancer has modulates excessive immune responses.12,13 Binding of Santiago, Chile (M Garrido MD);
improved in recent years with the development of PD-1 to its ligands (PD-L1 and PD-L2) on tumour cells Merck & Co, Kenilworth, NJ,
targeted drugs for patients with amenable mutations,1–5 suppresses T cells through a negative feedback loop, USA (G M Lubiniecki MD,
Y Shentu PhD, E Im MD,
only a small proportion of patients have these mutations, leading to evasion of the immune response.14–17
M Dolled-Filhart PhD); and
and most tumours become resistant to targeted Pembrolizumab (MK-3475) is a highly selective, David Geffen School of
treatment.6 Immunotherapy is a new paradigm for the humanised, IgG4 monoclonal antibody against PD-1. Medicine at the University of
treatment of non-small-cell lung cancer, and targeting Pembrolizumab 2 mg/kg given once every 3 weeks was California, Los Angeles,
Los Angeles, CA, USA
the PD-1 pathway is a promising therapeutic option.7–11 granted accelerated approval in the USA for the treatment
(E B Garon MD)
The PD-1 receptor is an immune checkpoint inhibitor of patients with metastatic non-small-cell lung cancer
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 1
Articles
Correspondence to:
Prof Roy S Herbst, Thoracic Panel: Research in context
Oncology Research Program,
Evidence before this study treated non-small-cell lung cancer. These data are the fi rst
Smilow Cancer Hospital, Yale
Comprehensive Cancer Center We searched PubMed on Nov 2, 2015, using the following terms: published report of a randomised, controlled clinical trial of
Yale School of Medicine, “PD-1 OR PD-L1 OR MK-3475 OR pembrolizumab OR non-small-cell lung cancer that prospectively shows the utility
333 Cedar Street, WWW221,
lambrolizumab OR Keytruda OR nivolumab OR BMS-936558 OR of PD-L1 as a biomarker. This study is also the fi rst of a PD-1
New Haven, CT 06520-8028, USA
Opdivo OR atezolizumab OR MPDL3280A OR BMS-936559 OR inhibitor for non-small-cell lung cancer to include patients who
roy.herbst@yale.edu
durvalumab OR MEDI4736 OR avelumab OR MSB0010718C OR received more than one line of previous treatment. Both
docetaxel” AND “non-small-cell lung cancer OR NSCLC”. The pembrolizumab 2 mg/kg and pembrolizumab 10 mg/kg every
search was not limited by date. We also searched the abstracts for 3 weeks provided superior overall survival compared with
the 2014 and 2015 American Society of Clinical Oncology Annual docetaxel, with similar outcomes for each pembrolizumab
Meetings, the 2014 European Society for Medical Oncology dose. Pembrolizumab was also associated with fewer
Congress, and the 2015 European Cancer Congress using the same high-grade toxic eff ects than was docetaxel.
search terms. We identifi ed three randomised trials of anti-PD-1 or
Implications of all the available evidence
anti-PD-L1 treatment versus docetaxel for non-small-cell lung
Our data support pembrolizumab 2 mg/kg given every 3 weeks
cancer: the CheckMate 017 study of nivolumab for squamous non-
as a new treatment option for patients with non-small-cell
small-cell lung cancer, the CheckMate 057 study of nivolumab for
lung cancer with a PD-L1 tumour proportion score of at least
non-squamous non-small-cell lung cancer, and the POPLAR study
1% that progressed after platinum-based chemotherapy and,
of atezolizumab for squamous and non-squamous non-small-cell
in those with an EGFR sensitising mutation or an ALK
lung cancer. We focused on the CheckMate studies because they
translocation, an appropriate tyrosine kinase inhibitor. These
are published in peer-reviewed journals.
data also validate the use of PD-L1 on tumour cells as a
Added value of this study biomarker to identify patients most likely to obtain a benefi t
Results of KEYNOTE-010 confi rm the effi cacy and safety of PD-1 from pembrolizumab.
inhibition with pembrolizumab in patients with previously
whose tumours express PD-L1 (as determined by test Response Evaluation Criteria in Solid Tumors (RECIST;
approved by the US Food and Drug Administration) with version 1.1)19 after two or more cycles of platinum-doublet
disease progression during or after platinum-containing chemotherapy, as well as an appropriate tyrosine kinase
chemotherapy. This approval was based on data from inhibitor for those with an EGFR-sensitising mutation or
550 patients with non-small-cell lung cancer enrolled in ALK gene rearrangement; measurable disease as per
the large, multicohort, phase 1b KEYNOTE-001 study.9,18 In investigator-assessed RECIST; an Eastern Cooperative
KEYNOTE-001, a PD-L1 tumour proportion score of 50% Oncology Group performance status of 0 or 1; provision of
or greater, defi ned as PD-L1 expression on at least 50% of a tumour sample; and PD-L1 expression on at least 1% of
See Online for appendix tumour cells (appendix p 5), was associated with better tumour cells (ie, a tumour proportion score ≥1%). Initially,
outcomes.9 any tumour sample was permitted for PD-L1 testing. The
We present results of KEYNOTE-010, the fi rst study protocol was later amended to require a new tumour
randomised comparison of pembrolizumab 2 mg/kg or sample for PD-L1 testing except when attempting to take a
10 mg/kg every 3 weeks versus standard-of-care treatment biopsy would be too risky. To be considered a new sample,
for PD-L1-positive non-small-cell lung cancer that no intervening treatment was permitted between the time
progressed after at least platinum-based chemotherapy. the sample was taken and initiation of study treatment.
This study is the fi rst active-control trial that enrolled The only exception was that patients receiving tyrosine
patients on the basis of prospective assessment of kinase inhibitors before the biopsy was taken were
tumour PD-L1 expression based on the association permitted to resume them after sample collection.
between higher PD-L1 expression and greater clinical 456 patients were enrolled on the basis of archival samples.
benefi t from pembrolizumab. Key exclusion criteria were previous treatment with
PD-1 checkpoint inhibitors or docetaxel, known active
Methods brain metastases or carcinomatous meningitis, active
Study design and participants autoimmune disease requiring systemic steroids, and
We did this randomised, controlled, phase 2/3 clinical trial interstitial lung disease or history of pneumonitis
at 202 academic medical centres in 24 countries (Argentina, requiring systemic steroids. The appendix shows all the
Australia, Belgium, Brazil, Canada, Chile, Czech Republic, inclusion and exclusion criteria.
Denmark, France, Germany, Greece, Hungary, Italy, Japan, The study protocol and all amendments were approved
Lithuania, Netherlands, Portugal, Russia, South Africa, by the appropriate institutional review boards and ethics
South Korea, Spain, Taiwan, UK, and USA). We included committees at each institution. The study was done in
patients aged at least 18 years, with progression as per accordance with the protocol, Good Clinical Practice
2 www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7
Articles
2699 patients screened
477 no PD-L1 assay result
2222 with PD-L1 assay results
747 had PD-L1-negative tumours
1475 had PD-L1–positive tumours
633 with TPS ≥50%
842 with TPS 1–49%
441 ineligible
1034 were randomly assigned
442 with TPS ≥50%
592 with TPS 1–49%
345 assigned to 271 discontinued 346 assigned to 271 discontinued 343 assigned to docetaxel 317 discontinued
pembrolizumab 2 mg/kg 93 with TPS ≥50% pembrolizumab 10 mg/kg 105 with TPS ≥50% 152 with TPS ≥50% 142 with TPS ≥50%
139 with TPS ≥50% 177 with TPS 1–49% 151 with TPS ≥50% 166 with TPS 1–49% 191 with TPS 1–49% 175 with TPS 1–49%
206 with TPS 1–49% 195 with TPS 1–49% 309 received treatment
339 received treatment 124 progressive 343 received treatment 126 progressive as assigned** 89 progressive
as assigned* disease§ as assigned|| disease§ 133 with TPS ≥50% disease§
137 with TPS ≥50% 34 with TPS ≥50% 151 with TPS ≥50% 49 with TPS ≥50% 176 with TPS 1–49% 40 with TPS ≥50%
202 with TPS 1–49% 90 with TPS 1–49% 192 with TPS 1–49% 77 with TPS 1–49% 49 with TPS 1–49%
34 adverse events 32 adverse events 47 adverse events
17 with TPS ≥50% 12 with TPS ≥50% 17 with TPS ≥50%
17 with TPS 1–49% 20 with TPS 1–49% 30 with TPS 1–49%
5 withdrew consent 10 withdrew consent 45 withdrew consent
3 with TPS ≥50% 6 with TPS ≥50% 22 with TPS ≥50%
2 with TPS 1–49% 4 with TPS 1–49% 23 with TPS 1–49%
21 died 21 died 21 died
74 ongoing† 9 with TPS ≥50% 75 ongoing† 5 with TPS ≥50% 11 ongoing† 6 with TPS ≥50%
46 with TPS ≥50% 12 with TPS 1–49% 46 with TPS ≥50% 16 with TPS 1–49% 5 with TPS ≥50% 15 with TPS 1–49%
28 with TPS 1–49% 82 physician 29 with TPS 1–49% 74 physician 6 with TPS 1–49% 113 physician decision¶
decision¶ decision¶ 56 with TPS ≥50%
28 with TPS ≥50% 30 with TPS ≥50% 57 with TPS 1–49%
344 intention-to-treat 54 with TPS 1–49% 346 intention-to-treat 44 with TPS 1–49% 343 intention-to-treat 1 protocol violation
population‡ 2 protocol population 1 protocol violation population 1 with TPS ≥50%
139 with TPS ≥50% violations 151 with TPS ≥50% 0 with TPS ≥50% 152 with TPS ≥50% 0 with TPS 1–49%
205 with TPS 1–49%‡ 1 with TPS ≥50% 195 with TPS 1–49% 1 with TPS 1–49% 191 with TPS 1–49% 1 other
339 safety population 1 with TPS 1–49% 343 safety population 7 other 309 safety population 0 with TPS ≥50%
137 with TPS ≥50% 3 other 151 with TPS ≥50% 3 with TPS ≥50% 133 with TPS ≥50% 1 with TPS 1–49%
202 with TPS 1–49% 1 with TPS ≥50% 192 with TPS 1–49% 4 with TPS 1–49% 176 with TPS 1–49% 15 completed‡‡
2 with TPS 1–49% 5 with TPS ≥50%
10 with TPS 1–49%
Figure 1: Trial profi le
TPS=tumour proportion score. *Three patients had clinical progression that rendered them ineligible before treatment could be started, two patients did not meet all eligibility criteria but were
incorrectly allocated to study treatment, and one patient was not treated because of physician decision. †Patients without a completed study medication discontinuation form. ‡One patient was
permitted to remain on treatment and was included in the safety analysis population, but because it would not be possible to adequately assess tumour response, the patient was excluded from the
effi cacy analysis population. §Includes only disease progression observed on radiological imaging. ¶Mainly clinical disease progression: for 80 (98%) of 82 patients in the pembrolizumab 2 mg/kg
group, 72 (97%) of 74 patients in the pembrolizumab 10 mg/kg group, and 84 (74%) of 113 in the docetaxel group. ||Two patients had adverse events (one had myocardial infarction, one had anaemia
with blood transfusion) that rendered them ineligible for study treatment, and one patient did not meet all eligibility criteria but was incorrectly allocated to study treatment. **34 patients withdrew
consent after learning they were allocated to the docetaxel group. ††Patients who discontinued docetaxel after receiving the maximum number of cycles approved by the local authorities were
considered to have completed study treatment.
guidelines, and the Declaration of Helsinki. All patients allocation schedule was generated by the system vendor
provided written informed consent. using a computerised randomised list generator. Patients
were stratifi ed by Eastern Oncology Cooperative Group
Randomisation and masking performance status (0 vs 1) and region (east Asia vs not east
Patients were randomly assigned (1:1:1) with a central Asia). A third stratifi cation variable, extent of PD-L1
interactive voice-response system to receive pembrolizumab expression (tumour proportion score ≥50% vs 1–49%), was
2 mg/kg intravenously over 30 min every 3 weeks, 10 mg/kg added after 441 patients were allocated and the PD-L1
intravenously over 30 min every 3 weeks, or docetaxel immuno histochemistry assay cutpoint was established.9
75 mg/m² intravenously over 1 h every 3 weeks. The Treatment was allocated in blocks of six in each stratum.
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 3
Articles
All patients Patients with tumour proportion score ≥50%
Pembrolizumab Pembrolizumab Docetaxel (n=343) Pembrolizumab Pembrolizumab Docetaxel (n=152)
2 mg/kg (n=344) 10 mg/kg (n=346) 2 mg/kg (n=139) 10 mg/kg (n=151)
Age (years) 63·0 (56·0–69·0) 63·0 (56·0–69·0) 62·0 (56·0–69·0) 62·0 (56·0–69·0) 64·0 (58·0–70·0) 60·0 (54·0–69·5)
Men 212 (62%) 213 (62%) 209 (61%) 81 (58%) 89 (59%) 93 (61%)
Race
White 246 (72%) 250 (72%) 251 (73%) 102 (73%) 111 (74%) 117 (77%)
Asian 73 (21%) 72 (21%) 72 (21%) 27 (19%) 28 (19%) 29 (19%)
Black or African American 13 (4%) 8 (2%) 7 (2%) 5 (4%) 5 (3%) 1 (1%)
Other 5 (1%) 5 (1%) 2 (1%) 2 (1%) 0 (0%) 1 (1%)
Unknown 7 (2%) 11 (3%) 11 (3%) 3 (2%) 7 (5%) 4 (3%)
Region
East Asia 64 (19%) 64 (18%) 62 (18%) 21 (15%) 25 (17%) 26 (17%)
Not east Asia 280 (81%) 282 (82%) 281 (82%) 118 (85%) 126 (83%) 126 (83%)
ECOG performance status*
0 112 (33%) 120 (35%) 116 (34%) 47 (34%) 47 (31%) 49 (32%)
1 229 (67%) 225 (65%) 224 (65%) 91 (65%) 104 (69%) 102 (67%)
2 3 (1%) 1 (<1%) 1 (<1%) 1 (1%) 0 (0%) 1 (1%)
3 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)
Unknown 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)
Histology
Squamous 76 (22%) 80 (23%) 66 (19%) 29 (21%) 41 (27%) 26 (17%)
Non-squamous 240 (70%) 244 (71%) 240 (70%) 95 (68%) 98 (65%) 111 (73%)
Other 9 (3%) 6 (2%) 10 (3%) 4 (3%) 5 (3%) 5 (3%)
Unknown 19 (6%) 16 (5%) 27 (8%) 11 (8%) 7 (5%) 10 (7%)
PD-L1 TPS
≥50% 139 (40%) 151 (44%) 152 (44%) 139 (100%) 151 (100%) 152 (100%)
1–49% 205 (60%) 195 (56%) 191 (56%) 0 (0%) 0 (0%) 0 (0%)
Smoking status
Former or current 279 (81%) 285 (82%) 269 (78%) 112 (81%) 122 (81%) 113 (74%)
Never 63 (18%) 60 (17%) 67 (20%) 26 (19%) 29 (19%) 34 (22%)
Unknown 2 (1%) 1 (<1%) 7 (2%) 1 (1%) 0 (0%) 5 (3%)
Stable brain metastases 56 (16%) 48 (14%) 48 (14%) 32 (23%) 23 (15%) 23 (15%)
EGFR status
Wild-type 293 (85%) 288 (83%) 294 (86%) 119 (86%) 127 (84%) 131 (86%)
Mutant 28 (8%) 32 (9%) 26 (8%) 8 (6%) 13 (9%) 12 (8%)
Unknown 23 (7%) 26 (8%) 23 (7%) 12 (9%) 11 (7%) 9 (6%)
ALK translocation
No 307 (89%) 305 (88%) 310 (90%) 120 (86%) 131 (87%) 137 (90%)
Yes 2 (1%) 4 (1%) 2 (1%) 2 (1%) 2 (1%) 1 (1%)
Unknown 35 (10%) 37 (11%) 31 (9%) 17 (12%) 18 (12%) 14 (9%)
Previous systemic therapies
Adjuvant 6 (2%) 7 (2%) 3 (1%) 2 (1%) 4 (3%) 3 (2%)
Neo-adjuvant 1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
(Table 1 continues on next page)
Patients, treating physicians, and the external data Procedures
monitoring committee were not masked to treatment Corticosteroid premedication was permitted for the
assignment. Personnel of the funder were not masked to docetaxel group. Treatment was continued for 24 months
individual treatment assignment but were masked to the or until disease progression, intolerable toxic eff ects,
PD-L1 tumour proportion score and aggregate data by physician decision, patient withdrawal, or other reasons.
treatment group during the study; the study statistician Patients who progressed according to investigator-
remained masked to treatment assignment until the assessed immune-related response criteria20 could
fi nal analysis was completed. remain on treatment until a confi rmatory scan done
4 www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7
Articles
All patients Patients with tumour proportion score ≥50%
Pembrolizumab Pembrolizumab Docetaxel (n=343) Pembrolizumab Pembrolizumab Docetaxel
2 mg/kg (n=344) 10 mg/kg (n=346) 2 mg/kg (n=139) 10 mg/kg (n=151) (n=152)
(Continued from previous page)
Number of lines for advanced disease
1 243 (71%) 235 (68%) 235 (69%) 97 (70%) 104 (69%) 109 (72%)
2 66 (19%) 69 (20%) 75 (22%) 30 (22%) 26 (17%) 25 (16%)
≥3 27 (8%) 34 (10%) 29 (8%) 10 (7%) 16 (11%) 15 (10%)
Unknown 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%)
Previous systemic treatment for advanced disease
Chemotherapy† 335 (97%) 337 (97%) 339 (99%) 137 (99%) 146 (97%) 149 (98%)
Immunotherapy 2 (1%) 1 (<1%) 1 (<1%) 1 (1%) 1 (1%) 0 (0%)
EGFR tyrosine kinase 40 (12%) 56 (16%) 47 (14%) 14 (10%) 20 (13%) 21 (14%)
inhibitor
ALK inhibitor 3 (1%) 5 (1%) 2 (1%) 3 (2%) 3 (2%) 1 (1%)
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. TPS=tumour proportion score. *For fi ve of the six patients who had and ECOG performance
status ≥2 during screening, the score improved to 1 by the time the patients were randomly allocated to treatment. †Patients whose disease progressed within 1 year of
completing platinum-based adjuvant therapy were also eligible.
Table 1: Baseline characteristics
4–6 weeks later. Per protocol, patients in the docetaxel and we analysed duration of response for all patients who
group were not permitted to cross over to receive had a best overall response of complete or partial
pembrolizumab. response according to RECIST (version 1.1) by central
Radiographic imaging was done every 9 weeks. review; we assessed safety in all patients who received at
Response was assessed as per RECIST version 1.1 by least one dose of study treatment. After one patient was
independent central review (for effi cacy) and as per allocated to and received pembrolizumab 2 mg/kg, it was
immune-related response criteria by investigator (to found that their pre-baseline scans were not compliant
inform treatment decisions). Adverse events were graded with the protocol. The patient was permitted to remain
according to the National Cancer Institute Common on treatment and was included in the safety analysis
Terminology Criteria for Adverse Events (version 4.0). population, but because it would not be possible to
PD-L1 expression was assessed at a central laboratory adequately assess tumour response, the patient was
with an immunohistochemistry assay (Dako; Carpinteria, excluded from the effi cacy analysis population.
CA, USA) with the murine 22C3 anti-human PD-L1
antibody (Merck; Kenilworth, NJ, USA), as previously Statistical analysis
described (appendix p 5).9 Because the lowest eff ective dose and the relative merit of
progression-free survival versus overall survival were
Outcomes unknown and the importance of PD-L1 staining was
The primary endpoints were overall survival (time from being validated when this study was designed, we
randomisation to death due to any cause) and assessed four primary outcomes at two doses. The
progression-free survival (time from randomisation to two doses were selected on the basis of pharmacological
radiologically confi rmed progressive disease or death models, and the statistical analysis plan appropriately
due to any cause) both in the total population (ie, tumour accounted for the multiple endpoints. Two prespecifi ed
proportion score of 1% or greater) and in patients with interim analyses were done by an unmasked statistician
tumour proportion score of 50% or greater. Secondary (appendix p 4). The data monitoring committee
endpoints were safety, response rate (percentage of recommended continuing the study as planned after both
patients with complete or partial response as per RECIST interim analyses. This study was designed to show a
version 1.1), and duration of response (time from fi rst diff erence in overall survival in patients with a tumour
evidence of response until disease progression or death). proportion score of 50% or greater. Because we assumed
We did prespecifi ed subgroup analyses of age, sex, that half of the total sample would have a tumour
Eastern Oncology Cooperative Group performance proportion score of 50% or greater, we believed that an
status, EGFR mutation status, and age of tumour sample. overall survival benefi t in this group would provide
We also did post-hoc exploratory subgroup analyses of enough power to show a benefi t for all primary endpoints.
tumour histology. The fi nal analysis was planned for when roughly
We analysed overall survival, progression-free survival, 200 deaths occurred across all treatment groups in
and response rate in the intention-to-treat population patients with a tumour proportion score of 50% or greater.
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 5
Articles
tumour proportion score of 50% or greater and to the
A
overall population.
100
For overall survival, data for patients who were alive or
90
lost to follow-up were censored at the time of last confi rmed
80
contact. For progression-free survival, data for patients
70 who had not progressed or were lost to follow-up were
60 censored at the time of last tumour assessment. For
50 duration of response, data for patients whose response was
40 ongoing at the time of the analysis or who discontinued
the study without radiological evidence of progression
30
were censored at the time of the last radiological
20
assessment showing response, data for patients who had
10
radiological disease progression after missing two
0
radiological assessments were censored at the time of the
0 5 10 15 20 25
Number at risk last radiological assessment showing response, and data
Pembrolizumab 2 mg/kg 139 110 51 20 3 0 for patients who initiated new cancer treatment without
Pembrolizumab 10 mg/kg 151 115 60 25 1 0
radiological evidence of disease progression were censored
Docetaxel 152 90 38 19 1 0
at the time of starting their new treatment.
We did the statistical analyses using SAS (version 9.3).
We used the Kaplan-Meier method to estimate overall
survival, progression-free survival, and duration of
response. We used the stratifi ed log-rank test to assess
treatment diff erences in progression-free survival and
overall survival; we used stratifi ed Cox proportional
hazard models with Efron’s method of tie handling to
calculate HRs and associated 95% CIs.21 We compared
response rate between treatment groups with the
Miettinen and Nurminen method.22 All primary and
subgroup analyses were stratifi ed with the randomisation
stratifi cation factors.
This study is registered with ClinicalTrials.gov,
NCT01905657.
Role of the funding source
The funder had a role in study design, analysis and
interpretation of data, and the writing of the report. The
Figure 2: Kaplan-Meier analysis of overall survival
funder maintained the study database. All authors had
(A) For patients with a PD-L1 tumour proportion score of 50% or greater. (B) For all patients.
full access to the data and had responsibility for the
Assuming that overall survival follows an exponential decision to submit for publication.
distribution with an expected median of 9 months in the
docetaxel group (based on previous studies), a hazard Results
ratio (HR) of 0·60 between pem brolizumab and docetaxel, Between Aug 28, 2013, and Feb 27, 2015, we screened
an enrolment period of 16 months, a minimum of 2699 patients for enrolment. Of the 2222 patients whose
8 months of follow-up after enrolment was complete to tumour samples were assessable for PD-L1 expression,
observe the required number of events, and a dropout 1475 (66%) had PD-L1 expression on at least 1% of
rate of 2% over 12 months, we calculated that we would tumour cells, including 633 (28%) with PD-L1 expression
need to enrol 460 patients with a tumour proportion score on at least 50% of tumour cells. 1034 (70%) of 1475 patients
of 50% or greater to provide at least 81% power to detect met the eligbility criteria and were enrolled in the study:
an HR of 0·55 for overall survival, with a one-sided α of 345 allocated to pembrolizumab 2 mg/kg, 346 to
0·00825 using the Hochberg procedure. We expected that pembrolizumab 10 mg/kg, and 343 to docetaxel (fi gure 1).
roughly 920 patients would be enrolled in total and that 991 patients received at least one dose of assigned study
550 patients would die by the fi nal analysis, giving the drug: 339 in the 2 mg/kg group, 343 in the 10 mg/kg
study at least 80% power to detect an HR of 0·70 for group, and 309 in the docetaxel group (fi gure 1). At the
overall survival in the total population. For the analysis of cutoff date of Sept 30, 2015, median follow-up was
progression-free survival, we used a threshold of p<0·001 13·1 months (IQR 8·6–17·7).
for signifi cance. The appendix (p 6) shows the multiplicity Baseline characteristics were as expected for patients
strategy we applied to the stratum of patients with a with advanced non-small-cell lung cancer and were
6 www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7
)%(
lavivrus
llarevO
B
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25
Time (months)
Number at risk
Pembrolizumab 2 mg/kg 344 259 115 49 12 0
Pembrolizumab 10 mg/kg 346 255 124 56 6 0
Docetaxel 343 212 79 33 1 0
)%(
lavivrus
llarevO
Pembrolizumab 2 mg/kg
Pembrolizumab 10 mg/kg
Docetaxel
Articles
balanced between groups (table 1). Most patients were
Events/patients (n) Hazard ratio (95% CI)
current or former smokers, had tumours of non-
squamous histology, and had received one line of Sex
previous systemic treatment (table 1). Few patients had Male 332/634 0·65 (0·52–0·81)
Female 189/399 0·69 (0·51–0·94)
EGFR-mutant or ALK-translocated tumours. Baseline
Age (years)
characteristics were similar in the 442 patients who had a
<65 317/604 0·63 (0·50–0·79)
PD-L1 tumour proportion score of 50% or greater
≥65 204/429 0·76 (0·57–1·02)
(table 1).
ECOG performance status
At the time of data cutoff , 521 patients had died:
0 149/348 0·73 (0·52–1·02)
172 (50%) of 344 in the pembrolizumab 2 mg/kg group, 1 367/678 0·63 (0·51–0·78)
156 (45%) of 346 in the pembrolizumab 10 mg/kg group, PD-L1 tumour proportion score
and 193 (56%) of 343 in the docetaxel group. 204 patents ≥50% 204/442 0·53 (0·40–0·70)
with a PD-L1 tumour proportion score of 50% or greater 1–49% 317/591 0·76 (0·60–0·96)
died: 58 (42%) of 139 in the pembrolizumab 2 mg/kg Tumour sample
group, 60 (40%) of 151 in the pembrolizumab 10 mg/kg Archival 266/455 0·70 (0·54–0·89)
group, and 86 (57%) of 152 in the docetaxel group. After New 255/578 0·64 (0·50–0·83)
discontinuation of study treatment, additional anti- Histology
Squamous 128/222 0·74 (0·50–1·09)
neoplastic treatment was received by 138 (40%) of
Adenocarcinoma 333/708 0·63 (0·50–0·79)
344 patients in the pembrolizumab 2 mg/kg group,
EGFR status
133 (38%) of 346 patients in the pembrolizumab 10 mg/kg
Mutant 46/86 0·88 (0·45–1·70)
group, and 151 (44%) of 343 patients in the docetaxel
Wild-type 447/875 0·66 (0·55–0·80)
group, including two (1%), six (2%), and 45 (13%),
Overall 521/1033 0·67 (0·56–0·80)
respectively, who received other immunotherapies
(appendix pp 8–9). 0·1 1 10
In patients with a PD-L1 tumour proportion score of
Favours pembrolizumab Favours docetaxel
50% or greater, the HR for overall survival for
pembrolizumab 2 mg/kg versus docetaxel was 0·54 Figure 3: Subgroup analysis of overall survival
Shows the comparison of the pooled pembrolizumab doses versus docetaxel. ECOG=Eastern Cooperative Oncology
(95% CI 0·38–0·77; p=0·0002), and for pembrolizumab
Group.
10 mg/kg versus docetaxel it was 0·50 (0·36–0·70;
p<0·0001). Median overall survival was 14·9 months 2 mg/kg group, 254 (73%) of 346 in the pembrolizumab
(95% CI 10·4–not reached) for the pembrolizumab 10 mg/kg group, and 256 (75%) of 343 in the docetaxel
2 mg/kg group, 17·3 months (11·8–not reached) for the group. In patients with a tumour proportion score of
pembrolizumab 10 mg/kg group, and 8·2 months 50% or greater, 304 patients had a progression-free
(6·4–10·7) for the docetaxel group (fi gure 2A). survival event (89 [64%] of 139, 97 [64%] of 151, and 118
In the total population, the HR for pembrolizumab [78%] of 152, respectively). Progression-free survival was
2 mg/kg versus docetaxel was 0·71 (95% CI 0·58–0·88; signifi cantly longer with pembrolizumab than with
p=0·0008) and the HR for pembrolizumab 10 mg/kg docetaxel in patients with a tumour proportion score of
versus docetaxel was 0·61 (0·49–0·75; p<0·0001). Median 50% or greater (fi gure 4A), with an HR of 0·59 (95% CI
overall survival was 10·4 months (95% CI 9·4–11·9) for 0·44–0·78; p=0·0001) for pembrolizumab 2 mg/kg
the pembrolizumab 2 mg/kg group, 12·7 months versus doxetaxel and 0·59 (0·45–0·78; p<0·0001) for
(10·0–17·3) for the pembrolizumab 10 mg/kg group, and pembrolizumab 10 mg/kg versus docetaxel. Median
8·5 months (95% CI, 7·5–9·8) for the docetaxel group progression-free survival was 5·0 months (95% CI
(fi gure 2B). 1-year overall survival was 43·2% versus 4·0–6·5) in the pembrolizumab 2 mg/kg group,
52·3% versus 34·6%. Overall survival was similar in the 5·2 months (4·1–8·1) in the pembrolizumab 10 mg/kg
two pembrolizumab groups both in patients with a PD-L1 group, and 4·1 months (3·6–4·3) in the docetaxel group.
tumour proportion score of 50% or greater (HR for For the total population, progression-free survival did
2 mg/kg vs 10 mg/kg 1·12, 95% CI 0·77–1·62) and in the not meet the prespecifi ed criterion for declaring statistical
total population (1·17, 0·94–1·45). Pembrolizumab signifi cance between pembrolizumab 2 mg/kg and
provided benefi t compared with docetaxel irrespective of doxetaxel (HR 0·88, 95% CI 0·74–1·05; p=0·07) or
whether archival or new tumour samples were used to between pembrolizumab 10 mg/kg and doxetaxel
assess PD-L1 expression. There was a signifi cant benefi t (HR 0·79, 0·66–0·94; p=0·004). Median progression-
for patients with non-squamous disease. For those with free survival was 3·9 months (95% CI 3·1–4·1) in the
squamous disease, the diff erence was not statistically pembrolizumab 2 mg/kg group, 4·0 months (2·7–4·3) in
signifi cant, but the data suggest a clinical benefi t in this the pembrolizumab 10 mg/kg group, and 4·0 months
group also (fi gure 3). (3·1–4·2) in the docetaxel group (fi gure 4B). Progression-
776 patients had died or had disease progression, free survival was similar for each pembrolizumab dose
including 266 (77%) of 344 in the pembrolizumab in patients with a tumour proportion score of 50% or
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 7
Articles
docetaxel group for patients with a tumour proportion
A
score of ≥50% or greater and 6 months in the docetaxel
100
group for all patients (appendix p 10).
90
In the safety population, the median duration of
80
treatment was 3·5 months (IQR 1·4–7·2) in the
70 pembrolizumab 2 mg/kg group, 3·5 months (1·4–7·0) in
60 the pembrolizumab 10 mg/kg group, and 2·0 months
50 (0·8–3·6) in the docetaxel group. Grade 3–5 adverse
40 events attributed to study treatment occurred in 43 (13%)
of 339 patients in the pembrolizumab 2 mg/kg group,
30
55 (16%) of 343 patients in the pembrolizumab 10 mg/kg
20
group, and 109 (35%) of 309 patients in the docetaxel
10
group (table 2). 15 (4%) of 339 patients, 17 (5%) of
0
343 patients, and 31 (10%) of 309 patients, respectively,
0 5 10 15 20 25
Number at risk permanently discontinued study drug because of
Pembrolizumab 2 mg/kg 139 66 29 6 0 0 treatment-related adverse events. Deaths attributed to
Pembrolizumab 10 mg/kg 151 72 36 12 0 0
study treatment occurred in three patients in the
Docetaxel 152 45 17 5 0 0
pembrolizumab 2 mg/kg group (two cases of
pneumonitis and one of pneumonia), three patients in
the pembrolizumab 10 mg/kg group (one case each of
myocardial infarction, pneumonia, and pneumonitis),
and fi ve patients in the docetaxel group (one case each of
acute cardiac failure, dehydration, febrile neutropenia,
interstitial lung disease, and respiratory tract infection).
Adverse events were as expected for pembrolizumab
and docetaxel (table 2, appendix pp 11–12). Adverse events
of special interest based on their likely immune aetiology,
irrespective of attribution to study treatment, occurred in
69 (20%) of 339 patients in the pembrolizumab 2 mg/kg
group and 64 (19%) of 343 patients in the pembrolizumab
10 mg/kg group. The most common of these events were
hypothyroidism, hyperthyroidism, and pneumonitis
(table 2). The only adverse events of special interest of
grade 3–5 severity that occurred in 1% or more of patients
were pneumonitis and severe skin reactions (table 2).
Figure 4: Kaplan-Meier analysis of progression-free survival Discussion
(A) For patients with a PD-L1 tumour proportion score of 50% or greater. (B) For all patients.
Pembrolizumab 2 mg/kg and 10 mg/kg every 3 weeks met
greater (HR 1·01, 95% CI 0·75–1·36) and in the total the prespecifi ed criteria for improved overall survival in all
population (1·09, 0·92–1·30). The eff ect on progression- patients (ie, PD-L1 tumour proportion score
free survival did not diff er by tumour histology (fi gure 5). of 1% or greater) and in those with a tumour proportion
Among patients with a tumour proportion score of score of 50% or greater—patients with high PD-L1
50% or greater, responses occurred in 42 (30%) of expression had an unprecedented benefi t for refractory
139 patients in the pembrolizumab 2 mg/kg group, 44 non-small-cell lung cancer. Both pembrolizumab groups
(29%) of 151 in the pembrolizumab 10 mg/kg group, and had signifi cantly improved progression-free survival in
12 (8%) of 152 in the docetaxel group (p<0·0001 for each patients with a tumour proportion score of 50% or greater,
pembrolizumab group vs docetaxel; appendix p 10). In and although the prespecifi ed criterion for declaring
the total population, 62 (18%) of 344 patients versus statistical signifi cance was not met, progression-free
64 (18%) of 346 patients versus 32 (9%) of 343 had survival was longer with pembrolizumab than with
responses (p=0·0005 for 2 mg/kg vs docetaxel and docetaxel for the total population. Responses to
p=0·0002 for 10 mg/kg vs docetaxel; appendix p 10). All pembrolizumab were durable, regardless of PD-L1
responses were partial responses. Median time to expression level. Pembrolizumab was associated with
response was 9 weeks in each treatment group (appendix fewer high-grade treatment-related adverse events than
p 10). Responses were longer in the pembrolizumab was docetaxel, despite a longer exposure. Immune-
groups than in the docetaxel group (appendix p 7), with a mediated adverse events, including pneumonitis, occurred
median duration of response not reached for either at manageable rates, although three (<1%) of 682 patients
pembrolizumab group compared with 8 months in the treated with pembrolizumab died because of pneumonitis.
8 www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7
)%(
lavivrus
eerf-noissergorP
B
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25
Time (months)
Number at risk
Pembrolizumab 2 mg/kg 344 122 46 12 1 0
Pembrolizumab 10 mg/kg 346 137 60 19 1 0
Docetaxel 343 103 27 6 0 0
)%(
lavivrus
eerf-noissergorP
Pembrolizumab 2 mg/kg
Pembrolizumab 10 mg/kg
Docetaxel
Articles
Median overall survival with docetaxel seemed to be
Events/patients (n) Hazard ratio (95% CI)
consistent with that previously reported (9 months),23
and there was no diff erence in survival with docetaxel Sex
among patients with a PD-L1 tumour proportion score of Male 488/634 0·78 (0·64–0·94)
Female 290/399 1·02 (0·78–1·32)
50% or greater or in the total population. Consistent with
Age (years)
KEYNOTE-001,9 pembrolizumab effi cacy was greater in
<65 466/604 0·84 (0·69–1·02)
patients with a tumour proportion score of 50% or
≥65 312/429 0·93 (0·72–1·19)
greater than in the overall population. Progression-free
ECOG performance s tatus
survival with pembrolizumab was superior to that of
0 251/348 1·08 (0·82–1·43)
docetaxel in patients with a tumour proportion score of
1 522/678 0·76 (0·63–0·91)
50% or greater, but not in the total population. However, PD-L1 tumour propo rtion score
overall survival with pembrolizumab was superior to that ≥50% 304/442 0·59 (0·46–0·74)
of docetaxel in both tumour proportion score strata, 1–49% 474/591 1·04 (0·85–1·27)
suggesting that progression-free survival might not Tumour sample
appropriately capture the true benefi t of pembrolizumab. Archival 367/455 0·81 (0·65–1·01)
The lack of a benefi t for progression-free survival despite New 411/578 0·86 (0·70–1·07)
a signifi cant overall survival benefi t was also reported in Histology
Squamous 182/222 0·86 (0·62–1·20)
the CheckMate 057 study of nivolumab versus docetaxel
Adenocarcinoma 522/708 0·86 (0·71–1·03)
for non-squamous non-small-cell lung cancer.8
EGFR status
Few patients assigned to pembrolizumab withdrew
Mutant 70/86 1·79 (0·94–3·42)
consent, whereas the incidence in the docetaxel group
Wild-type 660/875 0·83 (0·71–0·98)
was higher than what is typical in a phase 3 trial. Many of
Overall 778/1033 0·85 (0·73–0·98)
the patients allocated to docetaxel who withdrew consent
probably did so to seek anti-PD-1 treatment. A similarly 0·1 1 10
high percentage of patients in the CheckMate 057 trial
Favours pembrolizumab Favours docetaxel
who were assigned to docetaxel did not receive it (22 [8%]
of 290).8 This fi nding is not surprising given the many Figure 5: Subgroup analysis of progression-free survival
Shows the comparison of the pooled pembrolizumab doses versus docetaxel. ECOG=Eastern Cooperative Oncology
other studies of PD-1 inhibitors for non-small-cell lung
Group.
cancer that were ongoing during KEYNOTE-010. Patients
who withdrew and subsequently received another because of the small population size). In addition,
immunotherapy could aff ect overall survival. However, whereas both CheckMate studies limited enrolment to
any bias of this unplanned crossover would likely favour patients who received only one line of previous
the docetaxel group. Therefore, the high dropout rate in treatment for metastatic disease, almost one-third of
the docetaxel group does not diminish our confi dence in patients in KEYNOTE-010 received at least two lines of
the signifi cant survival benefi t for pembrolizumab. previous treatment.
Another limitation of this study is the incidence of EGFR Our data are the fi rst reported for lung cancer
mutation or ALK translocation, which was lower than prospectively showing the utility of PD-L1 as a biomarker;
would be expected in the general non-small-cell lung all patients derived a survival benefi t from pembro-
cancer population. Finally, because we excluded patients lizumab. This fi nding contrasts with the fi ndings of
with no PD-L1 tumour expression, we could not do studies of unselected populations. The assay used in
statistically meaningful analyses of the interaction KEYNOTE-010 was rigorously evaluated and validated
between PD-L1 expression and outcome by treatment before the study began9 and has been approved by the
allocation. Food and Drug Administration as a companion
Our results contribute to the growing evidence that diagnostic test. Our data indicate that assessment of
supports PD-1 pathway inhibition in non-small-cell lung PD-L1 in archival samples with this assay is appropriate
cancer.7,8,10,11,24 Although reports of treatment with because pembrolizumab provided superior overall
pembrolizumab and nivolumab have shown a survival survival regardless of the age of the sample. Among
benefi t for PD-1 inhibition, several aspects of patients with evaluable samples screened for enrolment
KEYNOTE-010 diff erentiate it from the CheckMate 017 in our study, two-thirds had a PD-L1 tumour proportion
and CheckMate 057 studies of nivolumab.7,8 Whereas score of 1% or greater, and more than a quarter had a
there were separate nivolumab studies for squamous7 score of 50% or greater. The higher proportion of patients
and non-squamous8 histology, KEYNOTE-010 enrolled with a score of 50% or greater in the enrolled population
patients regardless of histology. Our data suggest that, (43%) was a result of the exclusion of patients with
like nivolumab, pembrolizumab provides benefi t for PD-L1-negative tumours. Whether the benefi t of
squamous and non-squamous non-small-cell lung pembrolizumab extends to patients with a tumour
cancer (although the diff erence for squamous cell proportion score of less than 1% will require additional
disease was not statistically signifi cant, probably partly study. Ongoing studies are assessing pembrolizumab as
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 9
Articles
Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel (n=309)
(n=339) (n=343)
Any grade Grade 3–5 Any grade Grade 3–5 Any grade Grade 3–5
Related to treatment*
Any 215 (63%) 43 (13%) 226 (66%) 55 (16%) 251 (81%) 109 (35%)
Occurring in ≥10% of patients in any group
Decreased appetite 46 (14%) 3 (1%) 33 (10%) 1 (<1%) 49 (16%) 3 (1%)
Fatigue 46 (14%) 4 (1%) 49 (14%) 6 (2%) 76 (25%) 11 (4%)
Nausea 37 (11%) 1 (<1%) 31 (9%) 2 (1%) 45 (15%) 1 (<1%)
Rash 29 (9%) 1 (<1%) 44 (13%) 1 (<1%) 14 (5%) 0 (0%)
Diarrhoea 24 (7%) 2 (1%) 22 (6%) 0 (0%) 56 (18%) 7 (2%)
Asthenia 20 (6%) 1 (<1%) 19 (6%) 2 (1%) 35 (11%) 6 (2%)
Stomatitis 13 (4%) 0 (0%) 7 (2%) 1 (<1%) 43 (14%) 3 (1%)
Anaemia 10 (3%) 3 (1%) 14 (4%) 1 (<1%) 40 (13%) 5 (2%)
Alopecia 3 (1%) 0 (0%) 2 (1%) 0 (0%) 101 (33%) 2 (1%)
Neutropenia 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 44 (14%) 38 (12%)
Of special interest occurring in ≥2 patients in the pembrolizumab groups†
Hypothyroidism 28 (8%) 0 (0%) 28 (8%) 0 (0%) 1 (<1%) 0 (0%)
Pneumonitis‡ 16 (5%) 7 (2%) 15 (4%) 7 (2%) 6 (2%) 2 (1%)
Hyperthyroidism 12 (4%) 0 (0%) 20 (6%) 1 (<1%) 3 (1%) 0 (0%)
Colitis 4 (1%) 3 (1%) 2 (1%) 1 (<1%) 0 (0%) 0 (0%)
Severe skin reactions 4 (1%) 3 (1%) 7 (2%) 6 (2%) 2 (1%) 2 (1%)
Pancreatitis§ 3 (1%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Adrenal insuffi ciency 2 (1%) 0 (0%) 3 (1%) 1 (<1%) 0 (0%) 0 (0%)
Myositis 2 (1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%)
Thyroiditis 2 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Autoimmune hepatitis 1 (<1%) 1 (<1%) 2 (1%) 0 (0%) 0 (0%) 0 (0%)
Hypophysitis 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 0 (0%) 0 (0%)
Type 1 diabetes 1 (<1%) 1 (<1%) 2 (1%) 1 (<1%) 0 (0%) 0 (0%)
*Decided by the investigator. Events are listed in descending frequency in the pembrolizumab 2 mg/kg group. †Irrespective of attribution to study drug. Events are listed in
descending order of frequency in the pembrolizumab 2 mg/kg group. ‡Includes patients with interstitial lung disease (one in the pembrolizumab 2 mg/kg group, two in the
pembrolizumab 10 mg/kg group, and two in the docetaxel group). §Includes one patient with acute pancreatitis.
Table 2: Adverse events in the safety population
fi rst-line therapy (KEYNOTE-024, ClinicalTrials.gov Our fi ndings validate pembrolizumab as a new
number NCT02142738; and KEYNOTE-042, treatment option for patients with advanced non-small
ClinicalTrials.gov number NCT02220894) and as cell lung cancer who have received one or more previous
adjuvant therapy (PEARLS, ClinicalTrials.gov number treatment regimen and who have a tumour proportion
NCT02504372). These studies are enrolling patients score of at least 1%. These data also support the use of a
using diff erent biomarker cutpoints, and we await the dose of 2 mg/kg every 3 weeks and validate the use of
fi nal analyses to determine which cutpoint best predicts PD-L1 selection in this population.
the eff ectiveness of pembrolizumab monotherapy in
Contributors
these earlier lines of therapy. For those patients for whom RSH, GML, MD-F, and EBG designed the study. RSH, PB, D-WK, EF,
pembrolizumab monotherapy is not as eff ective as JPL-G, J-YH, JM, J-HK, CDA, M-JA, MM, MJF, GdC, MG, and EBG
collected data. RSH, M-JA, JLP-G, EI, and EBG analysed data. RSH, PB,
cytotoxic chemotherapy, combinations with
D-WK, EF, JLP-G, J-YH, JM, M-JA, MM, MJF, GdC, GML, YS, EI, and
chemotherapy25 or other immunotherapies26 might be
EBG interpreted the data. RSH and EI wrote the fi rst draft. All authors
needed. To augment patient identifi cation based on revised the report and approved the fi nal version.
PD-L1 expression, which may be limited by tumour Declaration of interests
heterogeneity and the dynamic nature of the immune RSH has received funding from Merck and served as an advisory board
microenvironment,27,28 other checkpoint molecules,29 member for AstraZeneca, Bristol-Myers Squibb, Genentech, and Roche.
PB has received grants from and served as an adviser for Merck. EF has
tumour infi ltrating cells,30 mutational load,31 blood-based
received consultation fees from Boehringer Ingelheim, Bristol-Myers
immune biomarkers,10 and infl ammatory gene Squibb, Merck Sharp & Dohme, Novartis, Pfi zer, and Roche, and
signatures32,33 could be explored. Additional studies will participated in company-sponsored speaker’s bureaux for Bristol-Myers
also be needed to determine the optimal duration of Squibb, Eli Lilly, and Novartis. JLP-G has received grants from Merck.
GdC has received personal fees from Merck Sharp & Dohme. GML, YS,
therapy for pembrolizumab and other anti-PD-1 drugs.
10 www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7
Articles
EI, and MD-F are employees of and hold stock options in Merck & Co. 16 Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited.
EBG has received grants from Merck, AstraZeneca, Bristol-Myers Annu Rev Immunol 2005; 23: 515–48.
Squibb, Eli Lilly, Genentech, Novartis, and Pfi zer. The other authors 17 Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1
declare no competing interests. immunoinhibitory receptor by a novel B7 family member leads to
negative regulation of lymphocyte activation. J Exp Med 2000;
Acknowledgments 192: 1027–34.
This study was funded by Merck & Co. We thank the patients and their 18 Fløtten Ø, Garon E, Arkenau HT, et al. Pembrolizumab 2 mg/kg
families and caregivers for participating in the study; LabCorp Clinical Q3W for previously treated, PD-L1-positive advanced NSCLC
Trials (Los Angeles, CA, USA) for performing the PD-L1 screening; Dako [abstract]. J Thorac Oncol 2015; 10 (suppl 2): 3024.
(Carpinteria, CA, USA) for contributing to the development of the PD-L1 19 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response
immunohistochemistry assay; Dean Harvey (LabCorp Clinical Trials) for evaluation criteria in solid tumours: revised RECIST guideline
providing the PD-L1 immunohistochemistry images shown in the (version 1.1). Eur J Cancer 2009; 45: 228–47.
appendix; James C Knowles, Ann Marie Mantz, Andrea J Rybak-Feiglin, 20 Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation
and Diane M Zawada (Merck & Co, Kenilworth, NJ, USA) for study of immune therapy activity in solid tumors: immune-related
support; and Roger Dansey (Merck & Co, Kenilworth, NJ, USA) for response criteria. Clin Cancer Res 2009; 15: 7412–20.
critical review of the report and study support. Medical writing support 21 Efron B. The effi ciency of Cox’s likelihood function for censored
in the preparation of this report was provided by Tricia Brown and data. J Am Stat Assoc 1977; 72: 557–65.
Melanie Leiby (The ApotheCom Merck oncology team, Yardley, PA, 22 Miettinen O, Nurminen M. Comparative analysis of two rates.
USA); this assistance was funded by Merck & Co. Stat Med 1985; 4: 213–26.
23 Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus
References
docetaxel versus placebo plus docetaxel for second-line treatment of
1 Mok TS, Wu YL, Thongprasert S, et al. Gefi tinib or
stage IV non-small-cell lung cancer after disease progression on
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med
platinum-based therapy (REVEL): a multicentre, double-blind,
2009; 361: 947–57.
randomised phase 3 trial. Lancet 2014; 384: 665–73.
2 Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus
24 Brahmer J, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers
chemotherapy in advanced ALK-positive lung cancer. N Engl J Med
of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC
2013; 368: 2385–94.
[abstract]. J Clin Oncol 2014; 32 (suppl): 8021.
3 Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged
25 Papadimitrakopoulou V, Patnaik A, Borghaei H, et al.
non-small-cell lung cancer. N Engl J Med 2014; 370: 1189–97.
Pembrolizumab (pembro; MK-3475) plus platinum doublet
4 Jänne PA, Yang PC, Kim DW, et al. AZD9291 in EGFR chemotherapy (PDC) as front-line therapy for advanced non-small
inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; cell lung cancer (NSCLC): KEYNOTE-021 cohorts A and C [abstract].
372: 1689–99. J Clin Oncol 2015; 33 (suppl): 8031.
5 Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in 26 Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of
EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as
372: 1700–09. second-line therapy for advanced non-small cell lung cancer
6 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in (NSCLC): KEYNOTE-021 cohort D [abstract]. J Clin Oncol 2015;
solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 33 (suppl): 8011.
11: 473–81. 27 Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small
7 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel cell lung cancer: current status and future direction. Cancer J 2014;
in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 20: 281–89.
2015; 373: 123–35. 28 McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment
8 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel of the heterogeneity of PD-L1 expression in non-small-cell lung
in advanced nonsquamous non-small-cell lung cancer. N Engl J Med cancer. JAMA Oncol 2015; published online Nov 12. DOI:10.1001/
2015; 373: 1627–39. jamaoncol.2015.3638.
9 Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment 29 Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the
of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018–28. B7 family, co-stimulates T-cell proliferation and interleukin-10
10 Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of secretion. Nat Med 1999; 12: 1365–69.
response to the anti-PD-L1 antibody MPDL3280A in cancer 30 Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1
patients. Nature 2014; 515: 563–67. mRNA expression is associated with increased TILs and better
11 Spira AI, Park K, Mazieres J, et al. Effi cacy, safety and predictive outcome in breast carcinomas. Clin Cancer Res 2014; 20: 2773–82.
biomarker results from a randomized phase II study comparing 31 Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape
MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) [abstract]. determines sensitivity to PD-1 blockade in non-small cell lung
J Clin Oncol 2015; 33 (suppl): 8010. cancer. Science 2015; 348: 124–28.
12 Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance 32 Ascierto PA, Capone M, Urba WJ, et al. The additional facet of
and autoimmunity. Immunol Rev 2010; 236: 219–42. immunoscore: immunoprofi ling as a possible predictive tool for
13 Pardoll DM. The blockade of immune checkpoints in cancer cancer treatment. J Transl Med 2013; 11: 54.
immunotherapy. Nat Rev Cancer 2012; 12: 252–64. 33 Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemokine
14 Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 gene signature identifi es lymph node-like structures in melanoma:
promotes T-cell apoptosis: a potential mechanism of immune potential for patient selection for immunotherapy? Sci Rep 2012;
evasion. Nat Med 2002; 8: 793–800. 2: 765.
15 Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N.
Involvement of PD-L1 on tumor cells in the escape from host
immune system and tumor immunotherapy by PD-L1 blockade.
Proc Natl Acad Sci USA 2002; 99: 12293–97.
www.thelancet.com Published online December 19, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01281-7 11
